[Immunglobulin Substitution Therapy in Hematological Patients with secondary Antibody Deficiency].

Braschler, Thomas R; Zeerleder, Sacha (2022). [Immunglobulin Substitution Therapy in Hematological Patients with secondary Antibody Deficiency]. Therapeutische Umschau, 79(6), pp. 295-300. Hogrefe 10.1024/0040-5930/a001364

Text 0040-5930_a001364.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (110kB)

Immunglobulin Substitution Therapy in Hematological Patients with secondary Antibody Deficiency Abstract. Hematological malignancies and immunochemotherapy are frequently associated with secondary cellular and humoral immunodeficiencies. Due to the growing application of effective therapeutic antibodies, and cellular therapies specifically targeting and hence depleting antibody producing cells (B- and plasma cells) the incidence of secondary antibody deficiencies in the daily practice is increasing. This article will provide a short overview of the etiology of secondary antibody deficiencies in hematological patients. Then, it will discuss the efficacy and indication of immunoglobulin substitution therapy in these patients and finally address the choice of the respective preparation.

Interest & Impact

Downloads

3 since deposited on 07 Oct 2022
2 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item